Figure 3: BRCA2-mutant PCa harbours multiple hallmarks of aggressive disease.
From: Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
(a) CNA, SNV and methylation profiles for MED12L and MED12. Patients are sorted based on MED12L CNA, methylation and SNV status. β-values are median dichotomized, as reflected by the background shading of each cell. The covariate bar at the top of the graph indicates BRCA2 status and Gleason score. (b) Multiple genes show differential rates of CNAs in tumours harbouring IDC and those not. Rows are genes, columns are samples. Red indicates copy-number gain; blue indicates copy-number loss; white indicates neutral copy-number status. The barplot to the right shows the differential frequency of mutation between IDC and IC components in BRCA2-mutant PCa.
